These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 39000539)

  • 1. 3D-QSAR, Scaffold Hopping, Virtual Screening, and Molecular Dynamics Simulations of Pyridin-2-one as mIDH1 Inhibitors.
    Wang Y; Jia S; Wang F; Jiang R; Yin X; Wang S; Jin R; Guo H; Tang Y; Wang Y
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
    Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
    J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR and scaffold hopping based designing of benzo[d]ox-azol-2(3H)-one and 2-oxazolo[4,5-b]pyridin-2(3H)-one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation.
    Verma H; Narendra G; Raju B; Kumar M; Jain SK; Tung GK; Singh PK; Silakari O
    Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200108. PubMed ID: 35618489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
    Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
    J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations.
    Zhang W; Bai H; Wang Y; Wang X; Jin R; Guo H; Lai H; Tang Y; Wang Y
    Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies.
    Boutalaka M; El Bahi S; Alaqarbeh M; El Alaouy MA; Koubi Y; Khatabi KE; Maghat H; Bouachrine M; Lakhlifi T
    J Biomol Struct Dyn; 2024 Jul; 42(10):5268-5287. PubMed ID: 37424193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Optimization of 2
    Rohde JM; Karavadhi S; Pragani R; Liu L; Fang Y; Zhang W; McIver A; Zheng H; Liu Q; Davis MI; Urban DJ; Lee TD; Cheff DM; Hollingshead M; Henderson MJ; Martinez NJ; Brimacombe KR; Yasgar A; Zhao W; Klumpp-Thomas C; Michael S; Covey J; Moore WJ; Stott GM; Li Z; Simeonov A; Jadhav A; Frye S; Hall MD; Shen M; Wang X; Patnaik S; Boxer MB
    J Med Chem; 2021 Apr; 64(8):4913-4946. PubMed ID: 33822623
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Shirvani P; Fassihi A
    J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation.
    Gao Y; Wang H; Wang J; Cheng M
    J Biomol Struct Dyn; 2020 Sep; 38(14):4119-4133. PubMed ID: 31556340
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Liu J; Feng K; Ren Y
    J Biomol Struct Dyn; 2019 Sep; 37(14):3803-3821. PubMed ID: 30261821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of methicillin resistance staphylococcus aureus inhibitors through 3D-QSAR, molecular docking and molecular dynamics simulations.
    Ballu S; Itteboina R; Sivan SK; Manga V
    Comput Biol Chem; 2018 Apr; 73():95-104. PubMed ID: 29475176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors.
    Ding L; Wang ZZ; Sun XD; Yang J; Ma CY; Li W; Liu HM
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3521-3528. PubMed ID: 28610981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QSAR analysis of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives isocitrate dehydrogenase inhibitors using Topomer CoMFA and HQSAR methods.
    Tong JB; Bian S; Zhang X; Luo D
    Mol Divers; 2022 Apr; 26(2):1017-1037. PubMed ID: 33974175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design Two Novel Tetrahydroquinoline Derivatives against Anticancer Target LSD1 with 3D-QSAR Model and Molecular Simulation.
    Xu Y; Fan B; Gao Y; Chen Y; Han D; Lu J; Liu T; Gao Q; Zhang JZ; Wang M
    Molecules; 2022 Nov; 27(23):. PubMed ID: 36500451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the Binding Mode of Reversible LSD1 Inhibitors Derived from Stilbene Derivatives by 3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation.
    Xu Y; He Z; Yang M; Gao Y; Jin L; Wang M; Zheng Y; Lu X; Zhang S; Wang C; Zhao Z; Zhao J; Gao Q; Duan Y
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31817721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the binding mechanism of substituted pyridine derivatives as effective and selective lysine-specific demethylase 1 inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations.
    Wang ZZ; Yang J; Sun XD; Ma CY; Gao QB; Ding L; Liu HM
    J Biomol Struct Dyn; 2019 Aug; 37(13):3482-3495. PubMed ID: 30175693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of novel monoamine oxidase B (MAO-B) inhibitors by combined application of docking-based alignment, 3D-QSAR, ADMET prediction, molecular dynamics simulation, and MM_GBSA binding free energy.
    El Aissouq A; Chedadi O; Bouachrine M; Ouammou A; Khalil F
    J Biomol Struct Dyn; 2023 Jul; 41(10):4667-4680. PubMed ID: 35510607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR, Molecular Docking, and MD Simulations of Anthraquinone Derivatives as PGAM1 Inhibitors.
    Wang Y; Guo Y; Qiang S; Jin R; Li Z; Tang Y; Leung ELH; Guo H; Yao X
    Front Pharmacol; 2021; 12():764351. PubMed ID: 34899321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.